Nov 7 (Reuters) - Sierra Oncology Inc SRRA.O :
* SIERRA ONCOLOGY ANNOUNCES PRICING OF $103 MILLION PUBLIC OFFERING OF CONVERTIBLE PREFERRED STOCK AND WARRANTS
* SIERRA ONCOLOGY - PRICED SERIES A WARRANTS TO PURCHASE UP TO 312.1 MILLION SHARES OF COMMON STOCK AT EXERCISE PRICE EQUAL TO $0.33 PER UNDERLYING SHARE
* SIERRA ONCOLOGY INC - INTENDS TO USE NET PROCEEDS FROM PUBLIC OFFERING TO FUND MOMENTUM, ITS PLANNED PHASE 3 CLINICAL TRIAL OF MOMELOTINIB
* SIERRA ONCOLOGY - EXPECTS TO APPOINT 4 NEW DIRECTORS WHO ARE AFFILIATED WITH VIVO CAPITAL, LONGITUDE CAPITAL, ORBIMED AND ABINGWORTH
* SIERRA ONCOLOGY INC - FOLLOWING SUCH APPOINTMENTS, CO EXPECTS ITS BOARD OF DIRECTORS WILL CONTINUE TO CONSIST OF EIGHT DIRECTORS